Skip to main content

Humacyte, Inc.

HUMA
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001818382

In the last 90 days, Humacyte, Inc. insiders filed 3 open-market purchases and 0 sales; 164 institutions reported holding it in 13F filings for Q2 2026, worth $57.3M in total; no superinvestor holds it.

Q3 2023 vs. Q2 2023

How the institutions holding Humacyte, Inc. changed between Q2 2023 and Q3 2023.

All holders in Q3 2023All holders in Q2 2023

13F holders of HUMA: Q2 2023 compared with Q3 2023
MeasureQ2 2023Q3 2023Change
Holders7583+8
Shares14.7M16.6M+1.88M (+12.8%)
Value$42.2M$48.7M+$6.45M (+15.3%)

New holders (16)

Institutions that held Humacyte, Inc. at the end of Q3 2023 but not at the end of Q2 2023.

Institutions new to HUMA in Q3 2023
InstitutionSharesValue% of portfolio
Millennium Management LLC1,226,409$3.59M0.00%
Lion Point Capital, LP235,000$688.5K0.63%
Marshall Wace, LLP176,207$516.3K0.00%
Two Sigma Investments, LP117,602$344.6K0.00%
Clough Capital Partners L P79,309$232.4K0.02%
Dimensional Fund Advisors LP62,237$182.4K0.00%
Verition Fund Management LLC39,356$115.3K0.00%
Bay Colony Advisory Group, Inc d/b/a Bay Colony Advisors17,950$52.6K0.01%
Private Management Group Inc15,500$45.4K0.00%
Commonwealth Equity Services, LLC12,580$37.0K0.00%
Powell Investment Advisors, LLC12,000$35.2K0.02%
Wolverine Trading, LLC11,861$34.8K0.00%
SG Americas Securities, LLC10,695$31.0K0.00%
Comerica Bank2,589$7.59K0.00%
US Bancorp2,500$7.33K0.00%
Byrne Asset Management LLC2,000$6.00K0.00%

Sold out (8)

Institutions that held Humacyte, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.

Institutions that sold out of HUMA in Q3 2023
InstitutionShares, Q2 2023Value, Q2 2023
Davidson Kempner Capital Management LP450,000$1.28M
Luminus Management LLC400,000$1.14M
Norges Bank374,176$1.07M
Josh Arnold Investment Consultant, LLC38,000$108.7K
Curi Capital35,440$101.4K
O'Dell Group, LLC1,500$4.29K
Wolverine Asset Management LLC1,132$3.24K
WealthPLAN Partners, LLC600$1.72K